房颤PCI患者口服抗凝联合P2Y12抑制剂的安全性Meta分析
结果显示,替格瑞洛(RR 1.36;95%CI 1.18-1.57)和普拉格雷(RR 2.11;95%CI 1.34-3.30)较氯吡格雷增加出血风险,而MACE无显著差异。
要点
- 房颤PCI患者口服抗凝联合氯吡格雷的出血风险低于替格瑞洛或普拉格雷。
- 替格瑞洛和普拉格雷与氯吡格雷相比,MACE风险无显著差异。
- 该分析中90%患者使用氯吡格雷,替格瑞洛和普拉格雷使用比例较低。
核心结论
- 在口服抗凝的房颤PCI患者中,氯吡格雷较替格瑞洛或普拉格雷出血率更低。
研究设计与样本
- 比较双联和三代抗血栓方案,按P2Y12抑制剂选择分析出血和MACE发生率。
- 采用Mantel-Haenszel法计算风险比(RR)及95%CI,异质性低(I2<25%)用固定效应模型,否则随机效应模型。
主要发现
- 与氯吡格雷相比,替格瑞洛(RR 1.36;95%CI 1.18-1.57)和普拉格雷(RR 2.11;95%CI 1.34-3.30)与出血率增加相关。
- 与氯吡格雷相比,替格瑞洛(RR 1.03;95%CI 0.65-1.62)和普拉格雷(RR 1.49;95%CI 0.69-3.24)的MACE率无显著差异。
临床怎么用
- 房颤PCI患者接受口服抗凝时,优先选择氯吡格雷可能降低出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors versus clopidogrel in combination with oral anticoagulation (OAC) with or without aspirin in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). METHODS: We performed a systematic review including both prospective and retrospective studies that compared dual and triple antithrombotic regimens for bleeding and major adverse cardiac events (MACE) in patients with AF undergoing PCI. We analysed rates of bleeding and MACE by P2Y12 inhibitor choice. Risk ratio (RR) 95% CIs were measured using the Mantel-Haenszel method. Where study heterogeneity was low (I2 <25%), we used the fixed effects model, otherwise the random effects model was used. RESULTS: A total of 22 014 patients were analysed from the seven studies included. Among patients treated with both OAC and P2Y12 inhibitor with or without aspirin, 90% (n=9708) were treated with clopidogrel, 8% (n=830) with ticagrelor, and 2% (n=191) with prasugrel. When compared with clopidogrel, use of ticagrelor (RR 1.36; 95% CI 1.18 to 1.57) and prasugrel (RR 2.11; 95% CI 1.34 to 3.30) were associated with increased rates of bleeding. Compared with clopidogrel, there were no significant differences in rates of MACE with ticagrelor (RR 1.03; 95% CI 0.65 to 1.62) or prasugrel (RR 1.49; 95% CI 0.69 to 3.24). CONCLUSION: Based on this meta-analysis, the use of clopidogrel is associated with a lower rate of bleeding compared with ticagrelor or prasugrel in patients with AF on OAC undergoing PCI.
引用
- Lupercio F, Giancaterino S, Villablanca PA, et al. P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. Heart. 2020. PMID: 32034008. doi:10.1136/heartjnl-2019-315963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。